Stockscreener 앱 받기
4.44
1.11%
-0.05
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Biotech executive Keating named to board of Berkeley Heights biopharma Kalaris - ROI-NJ
Kalaris Therapeutics appoints Laurie Keating to board - Investing.com
Kalaris Therapeutics Announces Board and Audit Committee Changes - TipRanks
Kalaris Appoints Laurie Keating to Board of Directors - The Manila Times
Press Release: Kalaris Appoints Laurie Keating to Board of Directors - Moomoo
Price to book forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
Kalaris Therapeutics, Inc.(NasdaqGM:KLRS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
Kalaris Therapeutics, Inc.(NasdaqGM: KLRS) added to Russell 3000E Growth Benchmark - marketscreener.com
Kalaris Therapeutics Inc. (KLRS) Q1 2026 Earnings: EPS Surprise Beats Estimates as Pre-Revenue Biotech Advances PipelineEarnings Analysis - dars.gov.et
Kalaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:KLRS) - TradingView
KLRS Forecast — Price Target — Prediction for 2027 - TradingView
Kalaris Therapeutics Inc (KLRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kalaris to present Phase 1a data on retinal drug at ASRS meeting - Investing.com UK
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling - Investing News Network
Kalaris Therapeutics to Present Phase 1a Data for TH103 at ASRS 2026 Annual Meeting - Quiver Quantitative
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling - GlobeNewswire Inc.
Kalaris Therapeutics Inc (KLRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kalaris Therapeutics Inc (KLRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kalaris Therapeutics Inc (KLRS) Institutional Confidence - TradingKey
Kalaris Therapeutics Inc (KLRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kalaris Therapeutics Inc (KLRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kalaris Therapeutics Inc (KLRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kalaris Therapeutics Inc (KLRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kalaris Therapeutics Climbs 7.8% as Biotech Momentum Builds (KLRS)Wave Extension - dars.gov.et
KLRS Initiates Coverage On by TD Cowen -- Rating Set to Buy - GuruFocus
TD Cowen initiates Kalaris stock coverage with buy rating - Investing.com UK
TD Cowen initiates Kalaris stock coverage with buy rating By Investing.com - Investing.com Australia
Kalaris Therapeutics initiated with a Buy at TD Cowen - TipRanks
KLRS SEC FilingsKalaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Kalaris to Present at Clinical Trials at the Summit 2026 - Investing News Network
First-in-human TH103 eye trial data to be presented at Las Vegas summit - Stock Titan
KLRS Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Clinical Development ProgressEPS Revision Trend - newsline.com
KLRS Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Development StageAnalyst Earnings Estimate - newsline.com
Why Is Kalaris Therapeutics Inc (KLRS) Stock Down Today? - Meyka
Kalaris Therapeutics Shareholders Back Board, Pay and Auditor - TipRanks
Kalaris Therapeutics (KLRS) director granted 9,000 stock options - Stock Titan
Kalaris Therapeutics (KLRS) director receives stock options for 9,000 shares - Stock Titan
Kalaris Therapeutics (KLRS) director receives 9,000-stock option grant - Stock Titan
[Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity - Stock Titan
Kalaris Therapeutics (KLRS) director awarded 9,000 stock options - Stock Titan
Kalaris Therapeutics (KLRS) director receives stock options on 9,000 shares - Stock Titan
Kalaris Therapeutics (KLRS) holders elect board, choose annual say-on-pay - Stock Titan
Kaskela Law LLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. Shareholders and Encourages Investors With Losses to Contact The FirmKLRS - ACCESS Newswire
Kalaris Therapeutics (KLRS) Slides 6.33% as Selling Pressure Mounts; Key Support in FocusMFI Overbought - newsline.com
Wedbush Maintains Kalaris Therapeutics(KLRS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Number of shareholders of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
KLRS Q1 2026 Earnings: Better-than-Expected Loss but Stock DeclinesReturn On Equity - dars.gov.et
KLRSKalaris Therapeutics Inc Stock Price and Quote - Finviz
Kalaris Therapeutics (KLRS) Surges 7.72% as Shares Approach Key ResistanceOvernight Profile - newsline.com
Kalaris Therapeutics director Akkaraju’s fund buys $1.18m stock By Investing.com - Investing.com Nigeria
Kalaris Therapeutics director Akkaraju’s fund buys $1.18m stock - Investing.com
Samsara entities boost control in Kalaris (KLRS) with 54.2% stake and intra-fund share deal - Stock Titan
Kalaris Therapeutics (KLRS) affiliate adds 244,300 KLRS shares - Stock Titan
Kalaris Therapeutics Inc. (KLRS) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Disciplined SpendingRevenue Growth Outlook - newsline.com
Kalaris Therapeutics (KLRS) Rallies +4.36% as Bulls Target $5.16 2026-05-20Covered Call ETF - Newser
Kalaris Therapeutics (KLRS) Falls -2.87% — Watching $4.82 Support 2026-05-15Open Signal Network - Newser
2.64%
자본화:
|
볼륨(24시간):